Retrospective Analysis on Relapsed/Refractory Aggressive Non Hodgkin Lymphoma Treated With Z-BEAM Plus ASCT

Azienda Ospedaliera Città della Salute e della Scienza di Torino

Status: Completed

Conditions: Refractory B-Cell Non-Hodgkin Lymphoma; Recurrent B-Cell Non-Hodgkin Lymphoma

Study type: Observational

Funder types: Other

Identifiers

NCT02992223

Oss_Z-BEAM

Details and patient eligibility

About

Evaluate if Y90 Ibritumomab Tiuxetan Radioimmunotherapy in addition to standard high dose chemotherapy followed by autologous stem cell transplant could improve prognosis in patients affected by relapsed/refractory aggressive non Hodgkin lymphoma

Enrollment: 58 patients

Sex: All

Ages: 19+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• High Risk Relapsed/refractory aggressive non-hodgkin lymphoma defined as:
• Progressive disease
• Early relapse (within 12 months from response)
• Recurrent relapse
• Treated with salvage chemotherapy followed by Y90 Ibritumomab Tiuxetan plus high-dose chemotherapy and Autologous stem cell transplant
• Age > 18 years
• Previous treatment with Rituximab
• Written informed consent

Exclusion criteria

• Patient with no complete data available for collection